SEC Company Response from Arbutus Biopharma Corp (ABUS) (CIK 0001447028) (ABUS) — Nov 16, 2021
Arbutus Biopharma Corp (ABUS) (CIK 0001447028)
Date: Nov. 16, 2021 · CIK: 0001447028 · Accession: 0001447028-21-000066
AI Filing Summary & Sentiment
File numbers found in text: 333-260782
Letter
Document
Arbutus Biopharma Corporation 701 Veterans Circle
Warminster, Pennsylvania 18974
November 16, 2021
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Arbutus Biopharma Corporation
Registration Statement on Form S-3
Filed November 4, 2021
File No. 333-260782
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Arbutus Biopharma Corporation hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) to become effective on November 18, 2021, at 4:00 p.m. Eastern Standard Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Stephen M. Nicolai of Hogan Lovells US LLP at (267) 675-4642.
ARBUTUS BIOPHARMA CORPORATION
By: /s/ David C. Hastings
Name: David C. Hastings
Title: Chief Financial Officer
Show Raw Text
CORRESP
1
filename1.htm
Document
Arbutus Biopharma Corporation 701 Veterans Circle
Warminster, Pennsylvania 18974
November 16, 2021
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Arbutus Biopharma Corporation
Registration Statement on Form S-3
Filed November 4, 2021
File No. 333-260782
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Arbutus Biopharma Corporation hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) to become effective on November 18, 2021, at 4:00 p.m. Eastern Standard Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Stephen M. Nicolai of Hogan Lovells US LLP at (267) 675-4642.
ARBUTUS BIOPHARMA CORPORATION
By: /s/ David C. Hastings
Name: David C. Hastings
Title: Chief Financial Officer